Biosimilars up - but not yet running
This article was originally published in Scrip
Executive Summary
The EU framework for biosimilar medicines is working and delivering products, but they are not penetrating the market as quickly as generics firms had hoped. This was one of the key messages to emerge from a recent conference in London organised by the European Generic medicines Association (EGA).
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.